Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of SEP-363856 in acutely psychotic patients with schizophrenia
jRCT2031250398Phase 3Active, not recruiting
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of ulotaront in schizophrenia (3 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Primary efficacy endpoint. Started Jan 2026; status: active, not recruiting.
02
Drugs
ulotaront
03
Conditions
schizophrenia
Beyond the preview
Go deeper on jRCT2031250398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250398.